ICU Medical (ICUI)
(Delayed Data from NSDQ)
$97.76 USD
+2.80 (2.94%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $97.77 +0.01 (0.01%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth D Momentum D VGM
ICU Medical (ICUI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$136.50 | $137.00 | $136.00 | 41.63% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for ICU Medical comes to $136.50. The forecasts range from a low of $136.00 to a high of $137.00. The average price target represents an increase of 41.63% from the last closing price of $96.38.
Analyst Price Targets (2 )
Broker Rating
ICU Medical currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 33.33% of all recommendations. A month ago, Strong Buy made up 33.33%, while Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 2.00 | 2.00 | 2.00 | 2.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/28/2024 | KeyBanc Capital Markets | Brett Fishbin | Strong Buy | Strong Buy |
12/15/2023 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
11/6/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 3 |
Average Target Price | $136.50 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 149 of 252 |
Current Quarter EPS Est: | 0.84 |